Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Premarket London: NMC to Launch Independent Audit Review

Published 12/23/2019, 02:19 AM
Updated 12/23/2019, 02:22 AM
© Reuters.

Investing.com -- Here is a summary of the most important regulatory news releases from the London Stock Exchange on Monday, 23rd December. Please refresh for updates.

  • UAE-focused hospital operator NMC Health (LON:NMC) said it has commissioned an independent review by external auditors to examine the allegations made last week by short seller Muddy Waters Research.

  • NMC’s shares lost half their value last week after Muddy Waters, owned by Carson Block, accused it of inflating its asset values, understating its debt and making undeclared related-party transactions.

  • Despite publishing a detailed rebuttal, NMC’s shares fell 15% on Friday alone after the Financial Times said it had held talks to raise off-balance sheet debt, a charge that indirectly supported one of Block’s allegations.

  • NMC said in its statement on Monday that it is “disappointed with the very material and, we believe, unwarranted share price reaction.”

    • BHP Group (LON:BHPB) said Andrew Mackenzie will leave the group at the end of March, three months earlier than scheduled.
    • Mackenzie is passing the reins as CEO to Mike Henry as of January 1, and the mining group said it’s confident the transition is “proceeding well and ahead of schedule.”
    • Mackenzie will receive around 7% less in stock under the company's long-term incentive program as a result.

  • GlaxoSmithKline (LON:GSK) confirmed that the U.S. Food and Drug Administration had refused to approve the long-acting HIV treatment made by its majority-owned subsidiary ViiV Healthcare.

  • “The reasons given in the Complete Response Letter relate to Chemistry Manufacturing and Controls (CMC),” GSK said. “There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date. ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application.”
    • 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

  • Reuters had originally reported the FDA’s rejection on Sunday.

    • Anglo American (LON:AAL) said it has received the next phase of its operating licence for its Minas-Rio tailings facility in Brazil.
    • "This is an important milestone for our Minas-Rio iron ore operation in Brazil towards reaching its full potential,” said Seamus French, CEO of Bulk Commodities. The company expects to produce 23 million tons of iron ore at Minas Rio in 2019, with an FOB cost of around $24/ton.

  • Defense group Cobham (LON:COB) published a list of the undertakings it had made to win government approval for its takeover by a U.S. private equity group.

  • They include maintenance of an HQ in the UK for each of its Communications & Connectivity, Aviation Services UK and Missions Systems businesses, and promises on the level of employment and R&D spending in the U.K.

    Latest comments

    Install Our App
    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.